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Varivax (varicella virus vaccine live [Oka/Merck]; Merck), a live attenuated varicella vaccine, is indicated for
vaccination against varicella in appropriate individuals 12 months of age. The 10-year safety profile for
Varivax is described using data submitted to Merck from routine global postmarketing surveillance, combined
with information from a Varicella Zoster Virus Identification Program, which uses polymerase chain reaction
(PCR) analysis to identify the presence and strain of VZV in selected specimens. There were 16,683 reports
worldwide voluntarily submitted to Merck, for an overall reporting rate of 3.4 reports/10,000 doses of vaccine
distributed. PCR analysis of vesicular rashes that occurred within the first 2 weeks after vaccination was more
likely to identify wild-type varicella-zoster virus (VZV), whereas the presence of Oka VZV was generally
associated with vesicular rashes that occurred 15–42 days after vaccination. Reports of breakthrough varicella
that occurred 142 days after vaccination were associated with wild-type VZV. Among 697 herpes zoster reports,
PCR analysis identified Oka VZV in 57 reports and wild-type VZV in 38 reports. There were no primary
neurologic adverse events associated with Oka VZV. Secondary transmission of Oka VZV from vaccine recip-
ients with postvaccination vesicular rashes was identified in 3 susceptible household contacts. Disseminated
Oka VZV was identified in 6 immunocompromised patients and 1 patient with Down syndrome. This review
has shown that the vaccine is generally safe and well tolerated.
Varivax (varicella virus vaccine live [Oka/Merck];
Merck), a live attenuated viral vaccine, became com-
mercially available in the United States on 1 May 1995.
The vaccine has been marketed worldwide in 46 coun-
tries, with ∼55 million doses distributed.
In the present article, we describe the safety profile
of varicella vaccine by use of spontaneous postmar-
keting adverse experience (AE) reports submitted to
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Merck, together with results from the Varicella Zoster
Virus Identification Program (VZVIP) during the first
10 years of marketing experience since the licensure of
Varivax.
METHODS
Postmarketing surveillance. The postmarketing re-
porting system for AEs is a passive, spontaneous, vol-
untary, incomplete reporting system. Merck’s World-
wide Adverse Experience System database contains
records of AEs spontaneously reported to the company
by health care professionals and consumers, as well as
case reports from the published literature. All reported
AEs temporally related to the administration of a vac-
cine are added to the database without regard to the
likelihood of a causal relationship and are coded in the
terminology used by the reporter.
Definitions. The following case definitions were
used to categorize AE data for analysis. A breakthrough
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Table 1. Varicella Zoster Virus Identification Program polymerase chain reaction results.









Rash 42 days after vaccination 37 42 17 9 25 130
Breakthrough varicella 0 16 10 1 6 33
Herpes zostera 57 38 16 4 47 162
Neurologic complicationsa 0 1 27 1 1 30
Secondary transmission 3 30 9 0 6 48
Total 97 127 79 15 85 403
NOTE. Data are no. of specimens. VZV, varicella-zoster virus.
a The herpes zoster specimens include 6 reported cases of herpes zoster with mild meningeal symptoms/meningitis, which
are included here under herpes zoster and are discussed in detail in the “HZ” subsection of Results.
Figure 1. Time to onset of rashes identified as Oka and wild-type
varicella-zoster virus (vVZV and wtVZV, respectively).
case of varicella was defined as a varicella-like rash (chickenpox)
in a vaccine recipient that occurred 142 days after vaccination
[1]. A secondary transmission case was defined as the docu-
mented presence of Oka VZV in a nonvaccinated contact of
an individual vaccinated with Varivax.
VZVIP. VZVIP uses polymerase chain reaction (PCR) anal-
ysis to distinguish the Oka VZV strain from the wild-type VZV
strain circulating in the United States. Clinical specimens were
collected from patients with 150 vesicular lesions occurring
within 42 days of vaccination, breakthrough cases of varicella,
herpes zoster (HZ), encephalitis, aseptic meningitis, cerebellar
ataxia, pneumonitis, and suspected secondary transmission.
PCR analysis and sample collection have been described else-
where [1, 2].
RESULTS
From 1 May 1995 through 30 April 2005, ∼55.7 million doses
of Varivax were distributed worldwide. Merck received 16,683
AE reports after the administration of varicella vaccine, for an
overall reporting rate of 3.4 AEs/10,000 doses distributed (da-
tabase query, 8 August 2005). AEs of interest that will be reviewed
here include rash within 42 days of vaccination, breakthrough
varicella, HZ, neurologic AEs, and secondary transmission of Oka
VZV. The PCR results for the AEs of interest are presented in
table 1.
Rashes within 42 days of vaccination. There were 3192
reports describing rashes occurring within 42 days after vac-
cination. Fifty-one percent were varicella-like rashes, 41% were
not well described or were nonspecific rashes, and ∼8% were
injection site rashes/vesicles. Sixty-five percent of the reported
rashes occurred within the first 14 days of receiving the vaccine,
and 89% occurred within the first 21 days.
The wild-type VZV rashes occurred a median of 8 days
(range, 1–20 days) after vaccination, whereas the Oka VZV
rashes occurred at a median of 21 days (range, 5–42 days) after
vaccination. The median number of lesions with wild-type VZV
rashes was 100 (range, 10–1000), whereas the median number
of lesions with Oka VZV rashes was 51 (range, 1–500). Thirty-
six (84%) of the 43 VZV rashes that occurred within the first
2 weeks after vaccination were identified as wild-type VZV, and
30 (83%) of 36 VZV rashes that occurred within 3–6 weeks
were identified as the Oka VZV strain (figure 1).
Eight of the patients in whom Oka VZV was identified in a
rash occurring !42 days after vaccination were immunocom-
promised. These included patients with undiagnosed HIV in-
fection, patients with undiagnosed primary immunodeficiency,
transplant recipients receiving high-dose steroids, and patients
with newly diagnosed systemic lupus erythematosus [1, 3, 4].
Additionally, of the 5 specimens with identified Oka VZV in
the fifth and sixth week after vaccination, 3 were from patients
who were immunocompromised, and 1 was from a patient who
had a history of Marfan syndrome.
Reports of breakthrough varicella. There were 5054 re-
ports of breakthrough varicella, for a reporting rate of 0.9 re-
ports/10,000 doses of vaccine distributed. Fifty-one reports
(1%) met the regulatory definition of “serious.” Thirty-eight
reports occurred in immunocompetent hosts, and 13 occurred
in immunocompromised patients. Of the 38 immunocompe-
tent hosts, 17 developed varicella described as “severe,” “full-
blown,” or “rash” (2 included vomiting and dehydration); 17
required treatment for secondary infection (cellulitis [12 pa-
tients], pneumonia [2 patients], sepsis [2 patients], and keratitis
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Patients, no. 57 38
Age of patients, median (range), years 2 (1–9) 4 (1–55)
Time to onset of reported HZ from vaccination, median (range) 318 days (23 days–
7.7 years)
588 days (4 days–
7.8 years)
Patients with postvaccination rash 42 days after vaccination, no. (%) 3 (5.3) 0
Site of injection correlated with the site of HZ, no. (%) 26 (46) 5 (13.2)
Patients with HZ occurring 42 days after vaccination, no. 2 10
Patients with HZ occurring 142 days after vaccination, no. 55 28
[1 patient]); 3 had neurologic complications (ataxia [2 patients]
and aseptic meningitis [1 patient]), and 1 experienced myo-
carditis with varicella. Oka VZV was not identified in any spec-
imens from breakthrough varicella.
The 13 reports in immunocompromised hosts occurred 50
days to 7 years after vaccination. The immunocompromising
conditions included cancer/leukemia (5 patients), use of high-
dose steroids to treat underlying conditions (4 patients), trans-
plant recipients (2 patients), undiagnosed primary immuno-
deficiency (1 patients), and failure to thrive (1 patient). Of the
7 specimens (4 of the 7 were analyzed by outside laboratories
and not through the VZVIP), 5 were positive for wild-type
VZV, and 2 were VZV positive but could not be further typed/
identified. Nine patients recovered, and the outcome in 1 case
is not reported. Three patients died of disseminated VZV in-
fection 1.7–7 years after vaccination (2 of the 3 specimens were
positive for wild-type VZV, and 1 was VZV positive, strain not
identified).
HZ. There were 697 reports of HZ occurring 1–3509 days
(median, 362 days) after vaccination in patients 13 months to
68 years of age (median age, 3.4 years). Four hundred patients
(65%) for whom age was reported were !5 years of age. Table
2 compares the HZ reports in which PCR analysis identified
Oka VZV and wild-type VZV strains.
The site of HZ was more likely to correlate with the site of
vaccine injection in reports in which Oka VZV was identified.
PCR was more likely to identify wild-type VZV than Oka VZV
if the time to onset was within 42 days of vaccination. However,
2 reports in which HZ was diagnosed within 42 days of vac-
cination had specimens in which Oka VZV was identified. One
of these reports was of a child with acute lymphocytic leukemia
diagnosed 10 days after vaccination with Varivax. The child
eventually developed HZ on 3 occasions: 23, 47, and 116 days
after vaccination. PCR analysis of a specimen from the last
episode of HZ identified Oka VZV. In the second report, Oka
VZV was present in a girl 5 years of age who developed an
HZ-like rash in the distribution of the second division of the
trigeminal nerve (right side of face and right eye) 25 days after
receiving Varivax.
Five patients developed meningitis in association with HZ.
Cerebrospinal fluid (CSF) specimens from these patients were
negative for VZV. The HZ rash specimens from 2 of the patients
had Oka VZV identified; however, in 1 of these reports, en-
terovirus was identified in the CSF analyzed at the Centers for
Disease Control and Prevention (CDC). A third patient had
wild-type VZV identified from an HZ rash specimen.
Additionally, 1 child who received Varivax at 2–3 years of
age had acute lymphocytic leukemia diagnosed at 4 years of
age. After treatment with 6-mercaptopurine weekly and meth-
otrexate monthly, he was hospitalized for HZ and mild me-
ningeal signs. A CSF specimen had Oka VZV identified. The
child recovered.
Neurologic AEs. Neurologic syndromes, such as encepha-
litis, aseptic meningitis, and cerebellar ataxia, have been re-
ported in the postmarketing environment after administration
of Varivax. There were 30 (CSF) specimens analyzed by PCR
(table 1) from patients with reports of such syndromes. The
reported AEs associated with these reports included encephalitis
(12 patients), meningitis (5 patients), ataxia (5 patients), trans-
verse myelitis (3 patients), seizures (3 patients), demyelinating
disorder (1 patient), and hemiparesis (1 patient). The 5 men-
ingitis reports associated with HZ listed in the “HZ” subsection
above are different from the cases of meningitis listed in this
subsection and are not included here. None of the CSF spec-
imens from these neurologic reports had Oka VZV identified
by PCR analysis. Several of these reports have been described
elsewhere [1, 4].
Secondary transmission. The VZVIP confirmed 3 cases of
secondary transmission of Oka VZV. The Oka VZV was present
in a 30-year-old pregnant woman who developed 100 vesicular
lesions 16 days after her 1-year-old son developed ∼30 vesicular
lesions 24 days after varicella vaccination. She elected to have
a therapeutic abortion, and the products of conception were
negative for VZV by PCR analysis [5]. In the second report,
the Oka VZV strain was also present in a 4-month-old boy
who developed 25 lesions 19 days after his 1-year-old sibling
developed 2 vesicular lesions 14 days after vaccination. The
third case in which Oka VZV was identified occurred in a 35-
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year-old father who developed 1100 lesions 17 days after his
1-year-old son developed 12 vesicular lesions 17 days after vac-
cination. In each of the 3 confirmed secondary-transmission
cases, the vaccine recipient had a postvaccination rash and had
close, household contact with the susceptible individual.
Additionally, there were 2 reported cases of possible sec-
ondary transmission, in which it was reported that the presence
of Oka VZV was identified by an outside laboratory [6, 7]. The
specimens for these cases were not analyzed through or con-
firmed by the VZVIP.
Disseminated Oka VZV infection. There were 7 reports of
disseminated VZV in which Oka VZV was identified. These
occurred in 6 patients with immunodeficiency disorders and 1
patient with Down syndrome. The 7 reports are described
briefly below.
1. A 13-month-old boy with a history of oral thrush for 3
months before vaccination developed a vesicular, dermatomal
rash 15 days after receiving Varivax, followed by respiratory
distress 83 days after vaccination. He was subsequently found
to be HIV positive [5]. PCR analysis of a bronchoalveolar lavage
(BAL) sample revealed the presence of Oka VZV.
2. A 5-year-old boy with severe cerebral palsy, seizure dis-
order, quadriplegia, and reactive airway disease treated with
intermittent steroid therapy was vaccinated 7 days after finish-
ing a steroid taper. Eight days later, the child restarted steroid
therapy; 2 days later, he developed a rash that was followed 7
days later by pneumonia. PCR analysis identified Oka VZV in
endotracheal secretions [1].
3. A 13-month-old boy with failure to thrive, recurrent
bronchiolitis, and oral candidiasis was hospitalized 10 days after
vaccination in respiratory distress with an enlarged liver and
elevated hepatic enzymes. A liver biopsy showed multifocal
necrosis, and Oka VZV was identified. He subsequently de-
veloped varicella and later received a diagnosis of combined
immune deficiency caused by an adenosine deaminase defi-
ciency [1].
4. An 11-year-old girl with mental retardation; a history of
congenital cytomegalovirus infection; and recurrent, presum-
ably viral, respiratory infections presented with a diffuse vesic-
ular rash and respiratory distress ∼5 weeks after vaccination.
She received a diagnosis of “post vaccine varicella pneumonitis”
and was subsequently diagnosed with a novel immunodefi-
ciency of NK T cells [8, 9]. PCR analyses of BAL and endo-
tracheal secretion specimens identified the presence of Oka
VZV.
5. A 13-month-old boy with DiGeorge syndrome post–
central shunt and Rastelli repair for tetralogy of Fallot was
vaccinated with Varivax and measles-mumps-rubella vaccine
(M-M-R II; Merck); 27 days later, he developed diffuse bilateral
pneumonitis. The patient was hospitalized 7 days later with
severe anemia, congestive heart failure, and bloody emesis. He
subsequently developed a vesicular rash with 5 lesions scattered
on the trunk. PCR analysis of vesicular and bronchial washings
identified Oka VZV. The CDC also reported that the tracheal
aspirate was positive for measles virus. The patient subsequently
died. Results of PCR testing of autopsy samples from the lungs
and lymph nodes were negative for VZV.
6. A 14-month-old boy with asthma developed a vesicular
rash 19 days after vaccination and was subsequently hospital-
ized with a disseminated rash, fevers, and elevated aspartate
aminotransferase and alanine aminotransferase levels. He had
treatment initiated with intravenous acyclovir. A liver biopsy
revealed multinucleated giant cells consistent with VZV infec-
tion, and an abdominal sonogram was consistent with visceral
dissemination. The child was diagnosed with a severe combined
immunodeficiency. PCR analysis of a lesion scab revealed the
presence of Oka VZV.
7. A 48-year-old male patient with Down syndrome de-
veloped a fever of 41.2C and was hospitalized with pneu-
monitis 13 days after vaccination. Two weeks after admission,
he developed a generalized rash. PCR results from lesion and
sputum specimens were positive for the Oka VZV strain. How-
ever, the sputum was not from BAL and may have been con-
taminated by oral lesions.
DISCUSSION
Although it has limitations, the strengths of postmarketing sur-
veillance include the following: it collects information on a large
number of individuals across a wide range of medical practices,
it provides data regarding unstudied uses or populations, and
it can detect rare, unexpected AEs [10]. Ten years of postmar-
keting surveillance of Varivax has been enhanced by the data
obtained through the VZVIP. The AEs described include rashes
within 42 days after vaccination, breakthrough reports of var-
icella, HZ, neurologic AEs, secondary transmission, and dis-
seminated Oka VZV cases.
With respect to vesicular rashes within 42 days after vacci-
nation, PCR analysis is more likely to identify wild-type VZV
in those rashes occurring within the first 2 weeks after vacci-
nation, whereas rashes occurring 15–42 days after vaccination
are more likely to be identified as Oka VZV. This trend is similar
to what has been previously reported [1].
Reports of varicella that occurred 142 days after vaccination
were associated with wild-type VZV. The majority (99%) of
these breakthrough reports were not serious by regulatory
definition.
Regarding reported HZ cases, when comparing Oka VZV
cases with wild-type VZV cases, those identified as Oka VZV
tended to occur more often in younger children (median age,
2 vs. 4 years), with a shorter median time to onset after vac-
cination (318 vs. 588 days) and with the site of HZ correlating
more often with the site of vaccination (46% vs. 13.2%).
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Reported neurological AEs after varicella vaccination in-
cluded encephalitis, meningitis, and cerebellar ataxia. There
have not been any primary neurologic cases in which PCR
analysis has identified the presence of Oka VZV in a normal
host.
The VZVIP has documented 3 cases of secondary transmis-
sion of the Oka VZV from a vaccine recipient to an unvaccin-
ated susceptible host. In all 3 instances, the vaccine recipient
experienced a rash and had close, household contact with the
susceptible individual.
There were 7 reports of disseminated Oka VZV reported in
6 immunocompromised patients and 1 patient with Down syn-
drome. Vaccination of individuals receiving immunosuppres-
sive therapy or with primary or acquired immunodeficiencies
is contraindicated, per the package circular for Varivax.
This 10-year review of spontaneous reporting after distri-
bution of 155 million doses of Varivax demonstrates that the
interpretation of postmarketing AE reports has been enhanced
by the VZVIP and that Varivax is generally well tolerated.
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